title: Targeted therapies: bevacizumab--has it reached its final resting place?
authors.affiliation: Nuffield Department of Clinical and Laboratory Sciences, John Radcliffe Hospital, Headley Way, Oxford OX3 9DU, UK. david.kerr@clinpharm.ox.ac.uk
authors.forename: David J
authors.initials: DJ
authors.lastname: Kerr
authors.forename: Annie M
authors.initials: AM
authors.lastname: Young
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D002986:Clinical Trials as Topic; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab